Columbus, OH – Inner State, Inc. a leading mental health and wellness research and development company focused on psychedelics, and The Ohio State University, one of the top-tier research universities in the U.S. have been awarded the first ever Drug Enforcement Administration (DEA) license to grow whole psilocybin mushrooms at U.S. university for research, significantly advancing the study of mental health treatment capabilities with naturally grown psychedelic mushrooms.
Mental health issues are on the rise with 20 million US citizens suffering from depression. Psilocybin has shown promise in treating a variety of mental health conditions, including depression, PTSD, anxiety, and addiction. However, due to its classification as a Schedule I drug, research into whole psilocybin mushrooms has been severely restricted in the United States.
“This license is a major milestone not only for Inner State and Ohio State but for the entire field of psychedelic research,” said Inner State CEO Ashley Walsh. “We are thrilled to be working with The Ohio State University to further explore the potential of the whole psilocybin mushroom.”
This landmark approval marks a significant step forward in the study of naturally grown psilocybin mushrooms.
“By combining cutting-edge techniques in genomics and metabolomics, we have the opportunity to obtain a high-resolution picture of the chemical diversity of mushrooms that have remained difficult to study for several decades,” noted Ohio State researchers Dr. Jason Slot and Dr. Kou-San Ju.
One potential advantage of natural mushrooms is that they contain psilocybin and other compounds that may have additional therapeutic benefits like the “entourage effect,” a synergistic interaction of different compounds that work together to produce a greater overall effect than one compound alone.
“We believe that there is more to discover in psilocybin mushrooms than just psilocybin. The whole mushroom is reported to have multi-dimensional healing properties that may help to cure mental health issues, relieve pain as well as improve the quality of palliative care for cancer,” said Walsh.
The license will allow Inner State and Ohio State to cultivate psilocybin mushrooms for research purposes only. All research will be conducted in accordance with strict DEA regulations and guidelines, ensuring the highest level of legal regulation and compliance.
Inner State, Inc. is a platform for better mental health tools with the mission to bridge the gap between wellness and science with research to create safe & effective mental health tools with optimized positive effects. Currently focused on developing novel molecules and unique compounds derived from psilocybin mushrooms in order to better understand their potential therapeutic applications and to develop new treatments that could help improve the lives of people suffering from these conditions. Inner State, Inc.’s
focus on this area reflects a commitment to improving mental health outcomes through innovative research and development.
